Assay Detail
Binding
CHEMBL3889183
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Inhibition Assay: The hERG inhibition study aims at quantifying the in vitro effects of compounds of the invention on the potassium-selective IKf current generated in normoxic conditions in stably transfected HEK 293 cells with the human ether-a-go-go-related gene (hERG).Whole-cell currents (acquisition by manual patch-clamp) elicited during a voltage pulse were recorded in baseline conditions and following application of tested compounds (5 minutes of exposure). The concentrations of tested compounds (0.3 uM; 3 uM; 10 uM; 30 uM) reflect a range believed to exceed the concentrations at expected efficacy doses in preclinical models.The pulses protocol applied is described as follow: the holding potential (every 3 seconds) was stepped from -80 mV to a maximum value of +40 mV, starting with -40 mV, in eight increments of +10 mV, for a period of 1 second. The membrane potential was then returned to -55 mV, after each of these incremented steps, for 1 second and finally repolarized to -80 mV for 1 second. The current density recorded were normalized against the baseline conditions and corrected for solvent effect and time-dependent current run-down using experimental design in test compound free conditions. Inhibition curves were obtained for compounds and the concentrations which decreased 50% of the current density determined in the baseline conditions (IC50) were determined. All compounds for which the IC50 value is above 10 uM are not considered to be potent inhibitors of the hERG channel whereas compounds with IC50 values below 1 uM are considered potent hERG channel inhibitors.
9
Total Activities
9
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Binding |
| Organism | Homo sapiens |
| Cell Type | Sf9 |
| Confidence | 8 — Homologous single protein target |
| Curated By | Autocuration |
Target
Voltage-gated inwardly rectifying potassium channel KCNH2 (CHEMBL240) ↗| Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
Publication
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 9 | 4.71 | 4.92 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL4112613 | — | — | 1 | 4.92 |
| CHEMBL3422016 | — | — | 1 | 4.77 |
| CHEMBL4114218 | — | — | 1 | 4.70 |
| CHEMBL4107668 | — | — | 1 | 4.60 |
| CHEMBL3422012 | — | — | 1 | 4.58 |
| CHEMBL3422010 | — | — | 1 | - |
| CHEMBL4107180 | — | — | 1 | - |
| CHEMBL3908229 | — | — | 1 | - |
| CHEMBL4108578 | — | — | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL4112613 | — | IC50 | = | 12000.0 | nM | 4.92 |
| CHEMBL3422016 | — | IC50 | = | 17000.0 | nM | 4.77 |
| CHEMBL4114218 | — | IC50 | = | 20000.0 | nM | 4.70 |
| CHEMBL4107668 | — | IC50 | = | 25000.0 | nM | 4.60 |
| CHEMBL3422012 | — | IC50 | = | 26000.0 | nM | 4.58 |
| CHEMBL3422010 | — | IC50 | > | 30000.0 | nM | - |
| CHEMBL4107180 | — | IC50 | > | 30000.0 | nM | - |
| CHEMBL3908229 | — | IC50 | > | 30000.0 | nM | - |
| CHEMBL4108578 | — | IC50 | > | 30000.0 | nM | - |